|
KMID : 1144320110430030245
|
|
감염과 화학요법
2011 Volume.43 No. 3 p.245 ~ p.250
|
|
|
Serial Testing of T-SPOT.TB Assays with Anti-Tuberculosis Therapy in Patients with Extrapulmonay Tuberculosis
|
|
Park Ki-Ho
Cho Oh-hyun
Ko Gwang-Beum
Lee Yumi
Park Hyun-jung
Park So-Yeon
Moon Song-Mi
Chong Yong-Pill
Lee Sang-Oh
Choi Sang-Ho
Kim Yang-Soo
Woo Jun-Hee
Kim Sung-Han
|
|
|
Abstract
|
|
|
Background: Limited data are available for the clinical utility of serial interferongamma producing T-cell response after initiation of treatment in patients with extrapulmonary tuberculosis (TB). We studied the serial TB-specific antigen T-cell responses measured using the T-SPOT.TB assay during the course of therapy.
Material and Methods : We prospectively enrolled adult patients who were newly diagnosed with active extrapulmonary TB over a 24-month period. All patients were given standard anti-TB treatment. Blood samples were obtained for T-SPOT. TB at diagnosis, as well as 1-, 3-, 6-, and 12-months after initiating anti-TB therapy.
Results: A total of 52 patients with extrapulmonary TB (38 confirmed and 14 probable TB) were included in the final nalysis. All patients had clinical and radiologic improvement after treatment and cured. T-SPOT.TB was positive for 90% at diagnosis, 100% at 1-, 3-, and 6-months, and 93% at 12-months after initiation of anti-TB therapy. There was no significant difference in median T-cell response between early secreting antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10) at all time points. Median T-cell response steadily increased up to 6 months and then decreased.
Conclusions: T-SPOT.TB assay remained positive after successful anti-TB treatment in most patients with extrapulmonary TB. Our data suggests that serial T-SPOT.TB has limited clinical utility as a surrogate marker of treatment response in patients with extrapulmonary TB.
|
|
|
KEYWORD
|
|
|
Tuberculosis, Enzyme-linked immunosorbent assay
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|